BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDTCompany ParticipantsXi-Yong Fu ...

Alternative splicing exhibits lineage-specific variability, with mammals and birds reaching the highest levels despite conserved intron-rich architectures, while unicellular eukaryotes and prokaryotes ...

Pancreatic cancer is mostly pancreatic ductal adenocarcinoma, with late-stage detection due to non-specific symptoms like jaundice and abdominal pain. Diagnosis involves imaging tests, biopsies, and ...

A new human liver organoid microarray developed by Cincinnati Children’s and Roche recreates immune-driven liver injury in ...

Researchers demonstrated that pancreatic β cells from type 2 diabetes donors can partially regain glucose responsiveness when ...

Researchers at Cincinnati Children's Hospital Medical Center in collaboration with Roche, have developed a next-generation ...

Researchers at Cincinnati Children’s Hospital Medical Center, in collaboration with Roche, have developed a next-generation ...

Researchers at Cincinnati Children's Hospital Medical Center in collaboration with Roche, have developed a next-generation ...

Academic scientists and pharmaceutical companies alike are embracing artificial intelligence, even as questions linger about ...